AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32941526 — intervention group
Group type: COMPARATOR
Intervention: Bench press with traditional stable loading
Number of subjects: 17
Study 32941526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench press with loads (2x5kg) attached as pendulums swinging forward/backwards
Number of subjects: 17
Study 32941526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench press with loads (2x5kg) attached as pendulums swinging left/right
Number of subjects: 17
Study 32941526 — intervention group
Group type: COMPARATOR
Intervention: Stable conditions
Number of subjects: 17
Study 32941526 — intervention group
Group type: EXPERIMENTAL
Intervention: Swing in the mediolateral direction
Number of subjects: 17
Study 32941526 — intervention group
Group type: EXPERIMENTAL
Intervention: Swing in the anteroposterior direction
Number of subjects: 17
Study 32941526 — intervention group
Group type: EXPERIMENTAL
Intervention: Swinging loads (both directions)
Number of subjects: 17
Study 35049164 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 9
Study 35049164 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Continuous Training (HICT)
Number of subjects: 9
Study 35049164 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Protocols
Number of subjects: 9
Study 35049164 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Protocols
Number of subjects: 9
Study 35049164 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Conditions
Number of subjects: 9
Study 35049164 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Conditions
Number of subjects: 9
Study 34284808 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID (with initial dose titration on days 1–6)
Number of subjects: 42
Study 34284808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 34284808 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 42
Study 35793101 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg balovaptan adult-equivalent dose
Number of subjects: 339
Study 35793101 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg balovaptan adult-equivalent dose
Number of subjects: 339
Study 35793101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 35793101 — intervention group
Group type: EXPERIMENTAL
Intervention: Balovaptan
Number of subjects: 339
Study 34414642 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power fractional CO2 laser every 4 weeks
Number of subjects: 25
Study 34414642 — intervention group
Group type: COMPARATOR
Intervention: TXA intradermal-microinjection every 2 weeks for 3 months
Number of subjects: 25
Study 36408238 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiaotaiwan (2-g JTW granules, b.i.d. for 7 days)
Number of subjects: 128
Study 36408238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2-g placebo granules, b.i.d. for 7 days)
Number of subjects: 128
Study 36286633 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA Ursofalk (Germany) at a dose of 10 mg/kg for at least 6 months
Number of subjects: 65
Study 36286633 — intervention group
Group type: COMPARATOR
Intervention: UDCA (another manufacturer) at a dose of 10 mg/kg for at least 6 months
Number of subjects: 65
Study 36286633 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA Ursofalk (Germany)
Number of subjects: 65
Study 36286633 — intervention group
Group type: COMPARATOR
Intervention: UDCA (another manufacturer)
Number of subjects: 65
Study 35771692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention related to lifestyle change for prediabetes; specific details on dosage and duration not available.
Number of subjects: 0
Study 35771692 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners (GPs) and nurses' views on prediabetes management; specific intervention details not available.
Number of subjects: 0
Study 35597718 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch applied 2–8 hours before puncture.
Number of subjects: 92
Study 35597718 — intervention group
Group type: COMPARATOR
Intervention: No treatment (only covering material).
Number of subjects: 92
Study 32318963 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 170
Study 32318963 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 170
Study 32318963 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 170
Study 32318963 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose DOACs (edoxaban or rivaroxaban)
Number of subjects: 170
Study 32318963 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-dose DOACs (edoxaban or rivaroxaban)
Number of subjects: 170
Study 32318963 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban and Warfarin (for hemopericardium)
Number of subjects: 170
Study 34332155 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated bilateral TBS at 80% resting motor threshold
Number of subjects: 300
Study 34332155 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated bilateral TBS at 120% resting motor threshold
Number of subjects: 300
Study 34332155 — intervention group
Group type: COMPARATOR
Intervention: Left unilateral 10 Hz rTMS
Number of subjects: 300
Study 32138728 — intervention group
Group type: EXPERIMENTAL
Intervention: Duck circovirus (DuCV) infection
Number of subjects: 848
Study 35144670 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression criteria
Number of subjects: 35
Study 35144670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trial feasibility
Number of subjects: 35
Study 35593677 — intervention group
Group type: EXPERIMENTAL
Intervention: repeated remote ischemic postconditioning (rIPostC)
Number of subjects: 88
Study 35593677 — intervention group
Group type: COMPARATOR
Intervention: sham-conditioning
Number of subjects: 88
Study 34311420 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 513
Study 34311420 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 513
Study 34311420 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 513
Study 32663852 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g amoxicillin + clavulanic acid 1 hour before surgery and 1 g amoxicillin + clavulanic acid twice a day for 5 days after surgery
Number of subjects: 75
Study 32663852 — intervention group
Group type: COMPARATOR
Intervention: No perioperative antibiotic therapy
Number of subjects: 75
Study 35819441 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure
Number of subjects: 0
Study 35819441 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33143514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 122421
Study 33143514 — intervention group
Group type: COMPARATOR
Intervention: No cholecystectomy (Control)
Number of subjects: 122421
Study 35405099 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB discontinuation in mild disease
Number of subjects: 659
Study 35405099 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB continuation in moderate disease
Number of subjects: 659
Study 35405099 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB discontinuation in moderate disease
Number of subjects: 659
Study 34333575 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use as the sole form of contraception (n = 137)
Number of subjects: 698
Study 34333575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual protection (using condoms and another form of contraception)
Number of subjects: 698
Study 34333575 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoms and the pill
Number of subjects: 698
Study 34333575 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 698
Study 32844723 — intervention group
Group type: EXPERIMENTAL
Intervention: RUC-4 at 0.05 mg/kg
Number of subjects: 32
Study 32844723 — intervention group
Group type: EXPERIMENTAL
Intervention: RUC-4 at 0.075 mg/kg
Number of subjects: 32
Study 32844723 — intervention group
Group type: COMPARATOR
Intervention: RUC-4 at 0.04 mg/kg
Number of subjects: 32
Study 35389050 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nomogram model incorporating deep learning predictive probability and clinical factors
Number of subjects: 104
Study 35389050 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model
Number of subjects: 104
Study 35389050 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model
Number of subjects: 104
Study 35389050 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size
Number of subjects: 104
Study 35389050 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial enhancement level
Number of subjects: 104
Study 35389050 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning predictive probability
Number of subjects: 104
Study 32493029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 75
Study 32493029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg/kg
Number of subjects: 75
Study 32493029 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 75
Study 33914304 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated management (IM) group: offline medical and nursing management combined with WeChat online management.
Number of subjects: 140
Study 33914304 — intervention group
Group type: COMPARATOR
Intervention: Control group: routine nursing intervention.
Number of subjects: 140
Study 35662314 — intervention group
Group type: EXPERIMENTAL
Intervention: PW‐PAD group
Number of subjects: 394
Study 35662314 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 394
Study 34785365 — intervention group
Group type: EXPERIMENTAL
Intervention: 10Hz M1‐rTMS over 2 weeks (real treatment)
Number of subjects: 27
Study 34785365 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (sham control)
Number of subjects: 27
Study 34050044 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic arm group (RG)
Number of subjects: 24
Study 34050044 — intervention group
Group type: COMPARATOR
Intervention: Free-hand group (FG)
Number of subjects: 24
Study 32615951 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourcing materials to promote HCV testing (administered once a week for two weeks)
Number of subjects: 1006
Study 32615951 — intervention group
Group type: COMPARATOR
Intervention: No promotional materials (control group)
Number of subjects: 1006
Study 32615951 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourcing materials to promote HCV testing
Number of subjects: 1006
Study 34597468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone based application (My Baby's Movements and Me)
Number of subjects: 3
Study 34597468 — intervention group
Group type: COMPARATOR
Intervention: Standard care (written brochure about fetal movements and clinical practice guideline)
Number of subjects: 3
Study 33826614 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomics-enabled arm (binimetinib)
Number of subjects: 27
Study 33826614 — intervention group
Group type: COMPARATOR
Intervention: Alternate treatment arm
Number of subjects: 27
Study 36164048 — intervention group
Group type: EXPERIMENTAL
Intervention: Pola-R-CHP
Number of subjects: 879
Study 36164048 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 879
Study 33737414 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap dance training (TD) for 16 weeks (60 min/session×3 sessions/week)
Number of subjects: 40
Study 33737414 — intervention group
Group type: COMPARATOR
Intervention: Control group attended four educational workshops (1 hour/session×1 session/month)
Number of subjects: 40
Study 32000630 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 6136
Study 36182728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Competency Evaluation system (multimedia items)
Number of subjects: 60
Study 36182728 — intervention group
Group type: COMPARATOR
Intervention: Text-based mobile test (control group)
Number of subjects: 60
Study 34329577 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.5 mg/kg on days 1 and 8, combined with ifosfamide (5 g/m2), carboplatin (AUC 5), and etoposide (100 mg/m2) for two 21-day cycles.
Number of subjects: 45
Study 34329577 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.5 mg/kg on days 1 and 8, combined with ifosfamide, carboplatin, and etoposide.
Number of subjects: 45
Study 33000415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongyan Spray (通咽喷雾剂) applied to the pharynx 30 min before examination
Number of subjects: 72
Study 33000415 — intervention group
Group type: COMPARATOR
Intervention: Purified water at room temperature (placebo)
Number of subjects: 72
Study 36065697 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling group (161 patients)
Number of subjects: 230
Study 36065697 — intervention group
Group type: COMPARATOR
Intervention: Validation group (69 patients)
Number of subjects: 230
Study 33258064 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise intervention
Number of subjects: 18
Study 33258064 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 36055230 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA-guided risk-stratification
Number of subjects: 0
Study 36055230 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 34862418 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 MHz mobile phone radiofrequency exposure
Number of subjects: 0
Study 34862418 — intervention group
Group type: COMPARATOR
Intervention: Control parameters (not specified)
Number of subjects: 0
Study 36373469 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Personalized Self-Care (APSC) program
Number of subjects: 180
Study 36373469 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study 35197420 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase at 0.6 mg/kg
Number of subjects: 126
Study 35197420 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 126
Study 33953542 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg empagliflozin
Number of subjects: 30
Study 33953542 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg lobeglitazone sulfate
Number of subjects: 30
Study 33953542 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 25 mg empagliflozin and 0.5 mg lobeglitazone sulfate
Number of subjects: 30
Study 32988385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (MTZ) 10 mg/kg for 30 days in HET mice
Number of subjects: 80
Study 32988385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (MTZ) for insomnia and mood disorders in RTT patients
Number of subjects: 80
Study 35417538 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG + Oral Polio Vaccine (OPV) immediately
Number of subjects: 1451
Study 35417538 — intervention group
Group type: COMPARATOR
Intervention: BCG + Oral Polio Vaccine (OPV) at hospital discharge
Number of subjects: 1451
Study 35417538 — intervention group
Group type: EXPERIMENTAL
Intervention: Unvaccinated neonates
Number of subjects: 1451
Study 35417538 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated neonates
Number of subjects: 1451
Study 34184474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampasse (5 mg/ml, 5 ml intravenously bolus slowly for 15 days)
Number of subjects: 124
Study 34184474 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride, 5 ml)
Number of subjects: 124
Study 34184474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampasse
Number of subjects: 124
Study 34184474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 32294619 — intervention group
Group type: COMPARATOR
Intervention: CON (17 minutes CON only)
Number of subjects: 12
Study 32294619 — intervention group
Group type: EXPERIMENTAL
Intervention: SELF (self-determined warm-up)
Number of subjects: 12
Study 32294619 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC (IPC + CON)
Number of subjects: 12
Study 32294619 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP (CON + PAP)
Number of subjects: 12
Study 35596578 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (8 mg)
Number of subjects: 40
Study 35596578 — intervention group
Group type: EXPERIMENTAL
Intervention: THC + CBD (8 mg THC + 10 mg CBD)
Number of subjects: 40
Study 35596578 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (600 mg, oral)
Number of subjects: 40
Study 35596578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33583165 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine alone (Group I)
Number of subjects: 31
Study 33583165 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine + Okada Purifying Therapy (Group II)
Number of subjects: 31
Study 33842006 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 70
Study 33842006 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 70
Study 33612615 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein Diet and Exercise (HPDE; n=15)
Number of subjects: 43
Study 33612615 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein Diet (HPD; n=15)
Number of subjects: 43
Study 33612615 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG; n=13)
Number of subjects: 43
Study 35350919 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intensivists and nurses
Number of subjects: 200
Study 35350919 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 34165151 — intervention group
Group type: EXPERIMENTAL
Intervention: CVRS2 design treatment
Number of subjects: 0
Study 34165151 — intervention group
Group type: COMPARATOR
Intervention: CVRS approach
Number of subjects: 0
Study 33345876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin-Metformin
Number of subjects: 66
Study 33345876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 66
Study 33345876 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 66
Study 33902611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) and ivermectin (IVM)
Number of subjects: 864
Study 33902611 — intervention group
Group type: COMPARATOR
Intervention: Control villages (not specified)
Number of subjects: 864
Study 33067493 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET) for 8 weeks
Number of subjects: 28
Study 33067493 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control for 8 weeks
Number of subjects: 28
Study 36104738 — intervention group
Group type: COMPARATOR
Intervention: Usual online ordering
Number of subjects: 1331
Study 33617194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic FX‐322
Number of subjects: 23
Study 33617194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 32559044 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontally accelerated osteogenic orthodontics (PAOO)
Number of subjects: 20
Study 32559044 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 35112424 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) intervention
Number of subjects: 397
Study 35112424 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 397
Study 34684336 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee + milk
Number of subjects: 14
Study 34684336 — intervention group
Group type: COMPARATOR
Intervention: Milk (control)
Number of subjects: 14
Study 33096362 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Safety Enhancement (MSE) simulation program with integrated technology
Number of subjects: 83
Study 33096362 — intervention group
Group type: COMPARATOR
Intervention: Standard training (Control)
Number of subjects: 83
Study 35660539 — intervention group
Group type: EXPERIMENTAL
Intervention: APOL1 genotyping with clinical decision support (CDS) results returned immediately
Number of subjects: 6650
Study 35660539 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving CDS results at 6 months
Number of subjects: 6650
Study 35660539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic testing for relevant antihypertensive medications
Number of subjects: 6650
Study 33020052 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100 μg or 4,000 units daily)
Number of subjects: 0
Study 33020052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35022783 — intervention group
Group type: EXPERIMENTAL
Intervention: suvorexant 10-20 mg nightly for 4 weeks
Number of subjects: 56
Study 35022783 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study 35022783 — intervention group
Group type: EXPERIMENTAL
Intervention: suvorexant
Number of subjects: 56
Study 33389236 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofloc technology (BFT)
Number of subjects: 64
Study 33389236 — intervention group
Group type: COMPARATOR
Intervention: Recirculating aquaculture systems (RAS)
Number of subjects: 64
Study 35604482 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous practice group (unsupervised at home every two weeks)
Number of subjects: 38
Study 35604482 — intervention group
Group type: COMPARATOR
Intervention: No-practice group
Number of subjects: 38
Study 32914847 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise60
Number of subjects: 70
Study 32914847 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise120
Number of subjects: 70
Study 32914847 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 32914847 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise60 and Noise120
Number of subjects: 70
Study 34383228 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter communicating collateral findings from a pragmatic clinical trial
Number of subjects: 4080
Study 34383228 — intervention group
Group type: COMPARATOR
Intervention: Letters that included a description of the clinical trial
Number of subjects: 4080
Study 35792493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg BID
Number of subjects: 1157
Study 35792493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157